Bethyl will be closed on Thursday, July 4 and Friday, July 5 in observation of the 4th of July holiday. We will re-open Monday, July 8.

The Speed Limit of the Cell Cycle

Contributed by Allison A. Curley, Ph.D.

The growth and division of cells, a process termed the cell cycle, consists of four phases in eukaryotes. DNA replication occurs during the synthesis (S) phase whereas cell division occurs during the mitosis (M) phase. Two additional gap phases (G1 and G2) that occur before the S and M phases, respectively, identify any problems during DNA replication and chromosome segregation, and pause the cycle in order to allow for appropriate repairs1. Cell cycle arrest primarily occurs through the inhibition of cyclin-dependent kinases (CDKs), whose activity is in turn regulated by various modulators. Cyclins are necessary to activate CDKs, while Ink4 proteins and those in the Cip and Kip family (such p21, p27, and p57) exert an inhibitory effect2. Proper regulation of the cell cycle is a critical process for normal cell biology, and the loss of control (for example, through mutations that produce abnormal CDK-cyclin complexes) leads to uninhibited cell growth and cancer3.

A February 2014 study published in Cell suggests that accelerating the speed of the cell cycle can aid in a somatic cell’s transition to pluripotency, a regression back to immaturity resulting in the capacity to become any cell type4. The 2006 discovery that adult skin cells can be converted to pluripotent stem cells was a very promising, both for research and medicine5. Researchers would now be able to generate an unlimited amount of neurons to study, and a patient’s own cells could be used to regenerate damaged tissue. However, in practice, reprogramming (thought to be a stochastic process) had proved more difficult than initially anticipated, and progress toward these goals was slow. Now researchers may have a short cut. The new study reports the existence of “privileged” somatic cells that are able to achieve pluripotency more readily due to their abnormally fast cell cycle. The finding suggests that increasing the speed of the cell cycle may be a way to preferentially shift a cell’s fate towards pluripotency, potentially allowing researchers to better harness the power of stem cells4.

The cell cycle, a fundamental process in all eukaryotic cells, is tightly regulated by a complex system of checks and balances. Researchers are beginning to understand that alterations to cell cycle speed can have drastic consequences on a cell’s fate, an observation with the potential for great gains in science and medicine.

 

Bethyl offers over 1,000 antibodies targeting proteins involved in cell cycle. View our portfolio.

 

Detection of human CDK4 by WB of 293T and HeLa lysate. Antibody: Rabbit anti-CDK4 (A304-224A). Secondary: HRP-conjugated goat anti-rabbit IgG (A120-101P) Detection of human CDK4 by WB of 293T and HeLa lysate. Antibody: Rabbit anti-CDK4 (A304-224A). Secondary: HRP-conjugated goat anti-rabbit IgG (A120-101P).
Detection of human CDK7 by WB of immunoprecipitates from HeLa lysate. Detection of human CDK7 by WB of immunoprecipitates from HeLa lysate. Antibodies: Rabbit anti-CDK7 recombinant monoclonal [BL-80-5D4] (A700-006). Secondary: ReliaBLOT® reagents (WB120).

Did you like this article?

Be sure to join Bethyl’s mailing list to receive limited-time promotions, new product information, and more articles like this one.

Join Mailing List

 

Trial sizes are cost-effective and ideal for comparison testing.
Trial size antibodies are ideal for comparisons between suppliers or various applications testing, and are cost effective. More than 6,000 trial-sized antibodies are currently available to over 3,300 protein targets, and more are being validated every month.
References

1. Bartek J, Lukas C, Lukas J. 2004. Checking on DNA damage in S phase. Nature Rev Mol Cell Biol. Oct;5:792–804.

2. Besson A, Dowdy SF, Roberts JM. 2008. CDK inhibitors: cell cycle regulators and beyond. Dev Cell. Feb;14(2):159-169.

3. Malumbers M, Barbacid M. 2009. Cell cycle, CDKs, and cancer: a changing paradigm. Nat Rev Cancer. Mar;9:153-166.

4. GuoS, Zi X, Schulz VP, Cheng J, Zhong M, Koochaki SH, Megyola CM, Pan X, Heydari K, Weissman SM, Gallagher PG, Krause DS, Fan R, Lu J. Nonstochastic reprogramming from a privileged somatic cell state. Cell. Feb 13;S0092-8674(14):72-75.

5. Okano H, Yamanaka S. 2014. iPS cell technologies: significance and applications to CNS regeneration and disease. Mol Brain. Mar 31;7(1):22.